---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-005868"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2023-04-13T23:59:59+00:00"
generated_at: "2026-06-17T02:44:51.931580+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Virios reports constructive FDA meeting for IMC-1 fibromyalgia; Long-COVID data expected June 2023

## Summary
- End-of-Phase 2 FDA meeting for IMC-1 was constructive; Company seeks guidance to advance to Phase 3.
- IMC-1 has been granted FDA Fast Track designation for fibromyalgia.
- Topline results from IMC-2 Long-COVID trial (valacyclovir/celecoxib) expected in June 2023.
- Company believes existing capital supports general and administrative operations into Q2 2024.

## SEC filing metadata
- accession: 0001558370-23-005868
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2023-04-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000155837023005868/0001558370-23-005868-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000155837023005868/tmb-20230413x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-005868
- JSON: https://secwatch.observer/filing/0001558370-23-005868.json
- Plain text: https://secwatch.observer/filing/0001558370-23-005868.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.